INTRODUCTION
Dogs in southern Africa are commonly infected with Ehrlichia canis, the agent of canine ehrlichiosis 8, 9, 11 . Self-cure is not known to occur and dogs remain infected until the organisms are cleared from the animal by appropriate therapy 3, 7, 14 . While in vivo studies have shown chloramphenicol, procaine penicillin G, sulfadimethoxine and sulfacetamide to be ineffective in the treatment of canine ehrlichiosis 6 , tetracycline therapy has been shown to be highly effective 3, 7, 16 . Treatment with tetracycline has, however, been reported to have numerous drawbacks such as vomiting, lack of owner compliance with the longterm therapy required and staining of dental enamel in young animals 13 . The use of imidocarb dipropionate, a drug used widely in Africa for the treatment of canine babesiosis, has been reported to have fewer drawbacks. The efficacy of the drug in the treatment of canine ehrlichiosis has been described 1, 10, 12, 13 . In these reports the treatment regimens varied considerably and it is unclear whether the efficacy of imidocarb dipropionate results from high plasma concentrations of the drug for a short time or lower concentrations maintained for longer periods 10 . Since Ehrlichia spp. are obligate intracellular organisms it has not been possible to determine the efficacy of antimicrobials on these bacteria using conventional susceptibility tests. Recently, however, assay systems have been developed to evaluate the susceptibilities of intracellular organisms to antimicrobials in vitro 4, 5, 15 . In this report we describe the results of experiments using these new methods to compare the effects of doxycycline and imidocarb dipropionate on E. canis.
MATERIALS AND METHODS
E. canis (Oklahoma strain) was grown in DH82 cells 18 in 175 cm 2 tissue culture flasks using minimal essential medium supplemented with 12.5 % foetal bovine serum and 2 mM L-glutamine. When cells gently scraped from the flask and stained with Diff-Quick (American Scientific Products, Obetz, Ohio) were found to be 30-50 % infected, the remaining cells were harvested using phosphate-buffered saline (pH 7.2) with 0.2 % EDTA. After addition of 15 ml fresh medium, the cell suspension was transferred to 96 well tissue culture plates (200 µl per well) and incubated at 37 °C until the cells became confluent. The medium was removed and each of the middle 6 rows in the plate were filled with 100 µl antimicrobial-free medium (controls) or medium containing 1 µg/ml doxycycline or 1.2, 2.4, 4.8 or 12 µg/ml imidocarb dipropionate (Imizol, Coopers Animal Health, England). The cells were incubated for 3 d before the medium was removed and replaced with fresh antimicrobial-free medium. Cells were harvested from one well in each row on days 1-9 after the addition of antimicrobial-containing medium and centrifuged onto glass slides using a cytospin at 600 g. After air-drying, the cells were stained with Diff-Quick and the ratio of infected to non-infected cells was independently determined by at least 2 of the authors with a Leitz microscope at ×400 magnification. All experiments were performed in triplicate and Student's t-test used to analyse data.
RESULTS
The addition of doxycycline (1 µg/ml) to DH82 cells infected with E. canis resulted in a decrease in the proportion of infected cells compared to non-treated controls (Fig. 1) . Following the removal of doxycycline from the cell culture medium, the proportion of infected cells continued to decline, indicating that the drug had a residual or rickettsiocidal effect on E. canis. These results are consistent with a previous report on in vitro antimicrobial sensitivity testing against E. canis 4 in which doxycycline and rifampacin were shown to have rickettsiocidal activity, while penicillin, gentamycin, co-trimoxazole, chloramphenicol, pefloxacin and erythromycin were found to be ineffective. The results are also consistent with reports that tetracycline therapy is effective in the treatment of canine ehrlichiosis in vivo 3, 7, 16, 17 . The concentrations of imidocarb dipropionate used in our experiments (1.2, 2.4, 4.8 and 12 µg/ml) were empirical as there are no data on the pharmacokinetics of imidocarb dipropionate in dogs following intramuscular or subcutaneous administration 10 . In sheep, the only species for which such data are available, an intramuscular injection of 4.5 mg/kg results in blood drug levels of about 4.5 µg/ml for 5 d. This subsequently decreases slowly by first-order kinetics, reaching concentrations of less than 1 µg/ml by day 28 2 . Similar doses of imidocarb dipropionate (5-7 mg/kg) administered subcutaneously 12 or intra-muscularly 1 have been reported to be effective in the treatment of canine ehrlichiosis.
On each day of our experiments there were very similar percentages of infected cells in the control wells and those to which imidocarb dipropionate was added at 1.2, 2.4, 4.8 or 12 µg/ml (results not shown). The differences between the percentage of infected cells in individual wells and the averages for the control and imidocarb dipropionate-treated wells on each day did not exceed 8 % (results not given). Similarly, there were no significant differences (p < 0.01) between the averages of the percentages of infected cells in wells treated with the different concentrations of imidocarb dipropionate and those of the untreated controls for the duration of the experiment (Fig. 1) .
DISCUSSION
Our findings indicate that the in vitro growth of E. canis is unaffected by shortterm (3 days) exposure to apparently low or high levels of imidocarb dipropionate. It therefore seems unlikely that the reported efficacy of imidocarb dipropionate against E. canis results from high plasma concentrations maintained for a short time. This is consistent with results of previous experiments 17 in which clinical ehrlichiosis was observed in dogs inoculated with blood from infected dogs treated with imidocarb dipropionate 14 days previously. It therefore appears likely that the successful treatment of E. canis infections with imidocarb dipropionate results from prolonged exposure of the organism to the drug. We would note, however, that previous reports of the efficacy of imidocarb dipropionate on E. canis can also be explained by self-cure 10 and circumstantial evidence has been presented that this might occur 11 . Further studies in which the possibility of self-cure in dogs with canine ehrlichiosis is assessed and also the effects of various treatment regimens with imidocarb dipropionate are required to finally resolve the question of the therapeutic efficacy of the drug.
